Reinhardt, Isabelle
Schmidt, Laura
Reske, Dirk
Zielasek, Jürgen
Braun, Gracia
Böttche, Maria
Boettcher, Johanna
Burchert, Sebastian
Glaesmer, Heide
Knaevelsrud, Christine
Konnopka, Alexander
Muntendorf, Louisa
Nohr, Laura
Paskuy, Sophia
Renneberg, Babette
Sierau, Susan
Stammel, Nadine
Wagner, Birgit
Wirz, Tina
Gouzoulis-Mayfrank, Euphrosyne
Funding for this research was provided by:
The research project is funded by the German Federal Ministry of Education and Research (FKZ: 01EF1806C, FKZ: 01EF1806C, FKZ: 01EF1806C)
Article History
Received: 21 November 2023
Accepted: 29 November 2023
First Online: 13 December 2023
Declarations
:
: The study was approved by the responsible ethics committee (Medical Association of North Rhine [Ärztekammer Nordrhein], Germany; EK2021113) and was conducted in accordance with the Declaration of Helsinki and the ICH guidelines for Good Clinical Practice (GCP). All participants will be informed orally and in writing about the aims and practical implementation of the study. This also includes a clarification about data security according to the latest legal standards. Participant inclusion will only be allowed after agreement to the written informed consent form. Informed consent will be obtained from all subjects. Participation is completely voluntary and can be terminated by the patient at any point without any consequences.
: Not applicable.
: Jürgen Zielasek is a member of the German Society for Psychiatry, Psychotherapy, Psychosomatics and Neurology (DGPPN). Jürgen Zielasek is a member of the scientific committee of the annual congress of the DGPPN, waiver of the participation fee and support of travel expenses. Jürgen Zielasek received the author’s fee Elsevier Verlag (textbook on schizophrenia). Jürgen Zielasek has shareholdings in biopharmaceutical companies unrelated to the topic of the contribution. All other authors have no competing interests to declare.